Statements (91)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquired |
gptkb:Genentech
gptkb:Spark_Therapeutics gptkb:Tibotec |
| gptkbp:acquisition |
gptkb:Genentech
gptkb:Flatiron_Health gptkb:Spark_Therapeutics gptkb:Tibotec |
| gptkbp:acquisition_year |
gptkb:2019
|
| gptkbp:awards |
multiple awards for innovation
recognized for workplace culture awarded for sustainability efforts recognized for corporate social responsibility awarded for workplace culture |
| gptkbp:biopharmaceuticals |
develops biopharmaceutical products.
|
| gptkbp:capital |
approximately 200 billion CHF (2021)
|
| gptkbp:ceo |
gptkb:Severin_Schwan
|
| gptkbp:clinical_trial |
collaborates with academic institutions
conducts numerous clinical trials globally collaborates with healthcare providers conducts thousands annually collaborates with regulatory agencies conducts extensive clinical research |
| gptkbp:collaboration |
collaborates with academic institutions
|
| gptkbp:collaborations |
engages in research collaborations with various entities
|
| gptkbp:community_engagement |
supports research funding
engages in community health initiatives supports local health initiatives supports education initiatives supports disaster relief efforts |
| gptkbp:community_health |
committed to improving global health outcomes
|
| gptkbp:conducts_research_on |
holds a prominent position in research and development
|
| gptkbp:covid-19_impact |
developed tests and treatments for COVID-19
developed tests and treatments |
| gptkbp:cultural_diversity |
committed to diversity and inclusion
|
| gptkbp:development |
diverse global workforce
|
| gptkbp:diagnosis |
develops various diagnostic tests
|
| gptkbp:employees |
around 100,000 (2020)
|
| gptkbp:financial_performance |
strong financial performance over the years
|
| gptkbp:founded |
gptkb:1896
|
| gptkbp:founded_in |
gptkb:1896
|
| gptkbp:founder |
gptkb:Fritz_Hoffmann-La_Roche
|
| gptkbp:global_presence |
operates in over 100 countries
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| gptkbp:healthcare |
provides comprehensive healthcare solutions
|
| https://www.w3.org/2000/01/rdf-schema#label |
Roche
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
invests heavily in R& D
invests heavily in biotechnology invests heavily in digital health invests heavily in personalized medicine |
| gptkbp:invention |
holds numerous patents in pharmaceuticals
|
| gptkbp:investment |
invests in innovative healthcare solutions
|
| gptkbp:investment_strategy |
consistently strong stock performance
|
| gptkbp:leadership |
recognized for strong leadership in the industry
|
| gptkbp:market_position |
one of the largest biotech companies in the world
|
| gptkbp:oncology_drugs |
produces several leading oncology drugs
|
| gptkbp:operates_in |
Pharmaceuticals
Diagnostics |
| gptkbp:partnership |
gptkb:Astra_Zeneca
gptkb:Foundation_Medicine gptkb:Illumina gptkb:Novartis |
| gptkbp:personalized_medicine |
pioneering personalized medicine approaches
|
| gptkbp:philanthropy |
gptkb:Roche_Foundation
|
| gptkbp:products |
biopharmaceuticals
oncology drugs diagnostics |
| gptkbp:provides_guidance_on |
contributes to clinical guidelines in healthcare
|
| gptkbp:research_and_development |
focus on oncology
focus on infectious diseases focus on neuroscience focus on immunology |
| gptkbp:research_focus |
oncology
central nervous system disorders infectious diseases immunology |
| gptkbp:revenue |
58.3 billion CHF (2020)
58.3 billion CHF (2022) |
| gptkbp:stock_exchange |
gptkb:SIX_Swiss_Exchange
|
| gptkbp:strategic_goals |
focus on patient-centered healthcare
|
| gptkbp:subsidiary |
gptkb:Roche_Diagnostics
gptkb:Roche_Pharma |
| gptkbp:sustainability |
focus on sustainable practices
|
| gptkbp:sustainability_initiatives |
focus on environmental responsibility
focus on social responsibility focus on governance |
| gptkbp:uses_technology |
strong focus on biotechnology
|
| gptkbp:bfsParent |
gptkb:biotechnology
gptkb:W3_C |
| gptkbp:bfsLayer |
3
|